How the Weaker Euro Is Impacting Biotech Earnings
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 270As Valeant Ups Salix Buyout, Will Endo Come Back?
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
Par Pharma Files for IPO
Par Pharmaceutical Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Salix Now Has 2 Merger Dance Partners
A new bid from Endo International has made the merger situation around Salix Pharmaceuticals much more complicated.
The Gamble That Did Not Pay Off
Zogenix has announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million.
4 Top Pharmaceutical Stocks to Buy for Market Safety
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
Short Sellers Get More Aggressive on Big Biotech
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen their short…
Can AcelRx Overcome Yet Another FDA Roadblock?
AcelRx Pharmaceuticals announced an update on the timing and potential content of its resubmission of the New Drug Application (NDA) for Zalviso.
The Next 3 Likely Biotech Buyout Candidates
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
Just How Expensive Is the Pharmacyclics Buyout?
News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21 billion.
Novogen Makes Big Step In Fighting Brain Cancer
ThinkstockNovogen Limited (NASDAQ: NVGN) confirmed Wednesday morning that one of its lead candidate products, TRXE-009, has shown potential to become an important new therapy for both adult and pediatric brain cancer. The most recent…
The 5 Most Loved Biotech Stocks of Portfolio Managers
A big part of the Nasdaq is biotech, and a new report from Cowen details the stocks that big money managers love and are staying with.
Oncolytics Newest Orphan Drug Designation
ThinkstockOncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin. Reolysin is the company’s lead product candidate that is designated for the treatment of…
Key Analyst Weighs In on Boston Scientific Acquisition
Merrill Lynch has weighed in on Boston Scientific acquiring the American Medical Systems urology portfolio of Endo International.